Adaptive Biotechnologies Corporation (ADPT) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $25.80 (+2.95% 1D, market cap $4.00B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ADPT ranks #285 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ADPT carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of 74.2%, and ROIC of -12.5%. By comparison, RLAY (Relay Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $3.79B) and IOVA (Iovance Biotherapeutics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $3.63B). Among the 5-stock peer group, ADPT leads on earnings multiple (N/A) while ADPT leads on capital efficiency (-12.5% ROIC).
Per ADPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001478320), Adaptive Biotechnologies Corporation generated $277.0M in revenue (+54.8% YoY), -$59.5M in net income, and -$48.9M in free cash flow against $512.7M in total assets and $126.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±11.4% realized swing band)
Altman Z-Score 6.32 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While ADPT currently carries a cautious 48/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($26.46) and Max Pain ($27.09) forces dealer call-delta covering toward $32.28.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Adaptive Biotechnologies Corporation (ADPT) surged +2.95% to $25.80, trading at 74% of its 52-week range ($12 – $30.74). Stretched risk/reward at current multiples (-13% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Adaptive Biotechnologies Corporation (ADPT) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Adaptive Biotechnologies Corporation (ADPT) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Adaptive Biotechnologies Corporation (ADPT) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Adaptive Biotechnologies Corporation (ADPT) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Adaptive Biotechnologies Corporation (ADPT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Adaptive Biotechnologies Corporation (ADPT) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Adaptive Biotechnologies Corporation (ADPT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Adaptive Biotechnologies Corporation (ADPT) market action, institutional positioning, and fundamental catalysts.
In matched multi-center cohorts, Telo Genomics is expanding comparative evaluation of blood-based TELO-MRD against Adaptive Biotechnologies' clonoSEQ next-generation sequencing MRD testing.Vancouver, British Columbia--(N
For questions about this article or underlying research, email help@trefis.com.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +54.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ADPT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ADPT. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Adaptive Biotechnologies Corporation (ADPT) ranks #285 by composite RQD confidence (48/100, grade D) and #177 by equity capitalization ($4.00B). Within this direct 5-issuer industry benchmark cohort, ADPT leads on earnings valuation at N/A trailing P/E, while ADPT leads on capital efficiency and profitability with -12.5% ROIC and 74.2% gross margin. TARS currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with ADPT at 48/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ADPT
ACTIVE
Adaptive Biotechnologies Corporation | D | 48/100 | — | 74.2% | -12.5% | +2.95% | $4.00B | Benchmark Subject |
| RLAY Relay Therapeutics Inc. | D- | 39/100 | — | — | -35.0% | +0.93% | $3.79B | /rlay-vs-adpt → |
| IOVA Iovance Biotherapeutics Inc. | D | 47/100 | — | 34.3% | -35.0% | +10.10% | $3.63B | /iova-vs-adpt → |
| TARS Tarsus Pharmaceuticals Inc. | D | 50/100 | — | — | -24.1% | -0.93% | $3.61B | /tars-vs-adpt → |
| CRSP CRISPR Therapeutics AG | D- | 35/100 | — | — | -30.6% | 0.00% | $4.83B | /crsp-vs-adpt → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Adaptive Biotechnologies Corporation (ADPT) reported GAAP revenue of $277.0M (+54.8% vs. FY2024 revenue of $179.0M , and +62.7% cumulative change since FY2023) , GAAP net income of -$59.5M, operating cash flow of -$46.0M, and free cash flow of -$48.9M (+50.5% YoY). On the balance sheet, ADPT closed FY2025 with $512.7M in total assets against $126.6M in total debt (Altman Z-Score: 6.32, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $277.0M | -$59.5M | -$46.0M | -$48.9M | $512.7M | $126.6M |
| FY2024 (FY) | 2024-12-31 | $179.0M | -$159.5M | -$95.2M | -$98.9M | $539.4M | $132.4M |
| FY2023 (FY) | 2023-12-31 | $170.3M | -$225.3M | -$156.3M | -$164.0M | $2.47B | $578.6M |
As of 2026-11-03, Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $25.80 (+2.95% 1D, market cap $4.00B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ADPT ranks #285 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ADPT carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of 74.2%, and ROIC of -12.5%. By comparison, RLAY (Relay Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $3.79B) and IOVA (Iovance Biotherapeutics Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -35.0%, cap $3.63B). Among the 5-stock peer group, ADPT leads on earnings multiple (N/A) while ADPT leads on capital efficiency (-12.5% ROIC).
Per ADPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001478320), Adaptive Biotechnologies Corporation generated $277.0M in revenue (+54.8% YoY), -$59.5M in net income, and -$48.9M in free cash flow against $512.7M in total assets and $126.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
ADPT last traded at $25.80 (+2.95% on volume of 1,512,902 shares), positioning the stock -2.49% below its 50-day simple moving average ($26.46) and +30.37% above its 200-day simple moving average ($19.79). Across its 52-week range of $12.00 to $30.74, ADPT sits at the 73.6% percentile with a 14-day RSI of 43.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.4% ($22.86 to $28.74).
Adaptive Biotechnologies Corporation (ADPT) earns a live Roarable RQD composite score of 48/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $25.80 (+2.95% 1D, market capitalization $4.00B).
Industry. Per the financials, reported revenue was $277.0M for FY 2025, up from $179.0M in FY 2024 and $170.3M in FY 2023. Gross margin is reported at 74.2%.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Adaptive Biotechnologies Corporation (ADPT) reported $277.0M in annual revenue (up from $179.0M in FY2024, +54.8% YoY) and -$59.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($170.3M revenue, -$225.3M net income) through FY2025, ADPT scaled operating cash flow to -$46.0M and free cash flow to -$48.9M, backed by $512.7M in total assets against $126.6M in total debt.
Operating in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), ADPT carries a macro regime beta of 1.01 and gross margin of 74.2%.
Real-time company headlines, analyst actions, and sector developments for Adaptive Biotechnologies Corporation (ADPT) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Adaptive Biotechnologies Corporation (ADPT) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Adaptive Biotechnologies Corporation (ADPT) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Adaptive Biotechnologies Corporation (ADPT) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Adaptive Biotechnologies Corporation (ADPT) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Adaptive Biotechnologies Corporation (ADPT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Adaptive Biotechnologies Corporation (ADPT) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Adaptive Biotechnologies Corporation (ADPT) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Adaptive Biotechnologies Corporation (ADPT) market action, institutional positioning, and fundamental catalysts.
The street is overcomplicating Adaptive Biotechnologies Corporation (ADPT). Revenue grew to $277.0M in FY 2025 while net losses narrowed to -$59.5M and debt fell to $126.6M, and institutional flow scores 17/20 in the RQD rating.. With an RQD score of 48/100 (D) and Forensic Balance Sheet at 14/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $28.77.
@MidwestValue Agree on the RQD 48/100 quality, though with 1.01 beta I'm scaling in with half-size at $26.64 and keeping dry powder in case we test $24.78.
I respect the product at Adaptive Biotechnologies Corporation, but the stock at $26.64 is a different story. ROIC of -12.5%, FCF yield of -1.09%, and an insider conviction score of 5/20 show the business is not yet generating cash and insiders are selling.. FCF yield is -1.09% and RQD sits at 48/100 (D) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: